» Articles » PMID: 17239007

Increased Level of Active GSK-3beta in Alzheimer's Disease and Accumulation in Argyrophilic Grains and in Neurones at Different Stages of Neurofibrillary Degeneration

Overview
Specialty Neurology
Date 2007 Jan 24
PMID 17239007
Citations 171
Authors
Affiliations
Soon will be listed here.
Abstract

The somatodendritic accumulation of hyperphosphorylated tau proteins is an early event preceding the appearance of neurofibrillary tangles (NFT) in Alzheimer's disease (AD) and might be necessary for their formation. Glycogen synthase kinase-3beta (GSK-3beta) is a physiological kinase for tau that generates many tau phosphorylation sites identified in NFT and in other tau-positive inclusions. We have studied the cellular distribution and the expression of the active form of GSK-3beta (GSK-3 pTyr216) in AD patients, in argyrophilic grain disease and in diffuse Lewy body disease. By Western blotting analysis, a significant increase in the level of GSK-3 (pTyr216) was observed in the frontal cortex of AD patients. A population of neurones showed a somatodendritic accumulation of GSK-3 (pTyr216) but not of the inactive form of GSK-3beta (GSK-3 pSer9). Most of these GSK-3 (pTyr216)-positive cells were positive for six different phosphotau epitopes known to be generated by GSK-3beta. By using a quadruple labelling method using GSK-3 (pTyr216) and phosphotau immunolabelling combined with Gallyas and DAPI staining, we examined neurones containing a somatodendritic GSK-3 (pTyr216) immunoreactivity at different stages of neurodegeneration. A majority of neurones at the pretangle stage without Gallyas-positive inclusions were GSK-3 (pTyr216) positive and this GSK-3 (pTyr216) immunoreactivity remained in most cells containing Gallyas and phosphotau-positive inclusions excepted in extracellular NFT. A GSK-3 (pTyr216) immunoreactivity was present in argyrophilic grains but not in cortical Lewy bodies. These results directly suggest that the activity of GSK-3beta is increased in AD and that somatodendritic accumulation and activation of GSK-3beta is an early event preceding and accompanying the formation of NFT and of other tau-positive inclusions.

Citing Articles

RhoA/ROCK/GSK3β Signaling: A Keystone in Understanding Alzheimer's Disease.

Medd M, Yon J, Dong H Curr Issues Mol Biol. 2025; 47(2).

PMID: 39996845 PMC: 11854763. DOI: 10.3390/cimb47020124.


Triple-Target Inhibition of Cholinesterase, Amyloid Aggregation, and GSK3β to Ameliorate Cognitive Deficits and Neuropathology in the Triple-Transgenic Mouse Model of Alzheimer's Disease.

He J, Sun S, Wang H, Ying Z, Tam K Neurosci Bull. 2025; .

PMID: 39907971 DOI: 10.1007/s12264-025-01354-y.


CRISPRi-based screens in iAssembloids to elucidate neuron-glia interactions.

Li E, Benitez C, Boggess S, Koontz M, Rose I, Martinez D Neuron. 2025; 113(5):701-718.e8.

PMID: 39814010 PMC: 11886924. DOI: 10.1016/j.neuron.2024.12.016.


Molecular Signaling Pathways of Quercetin in Alzheimer's Disease: A Promising Arena.

Alsaleem M, Al-Kuraishy H, Al-Gareeb A, Albuhadily A, Alrouji M, Yassen A Cell Mol Neurobiol. 2024; 45(1):8.

PMID: 39719518 PMC: 11668837. DOI: 10.1007/s10571-024-01526-w.


GSK3β phosphorylation catalyzes the aggregation of tau into Alzheimer's disease-like filaments.

Chakraborty P, de Opakua A, Purslow J, Fromm S, Chatterjee D, Zachrdla M Proc Natl Acad Sci U S A. 2024; 121(52):e2414176121.

PMID: 39693350 PMC: 11670061. DOI: 10.1073/pnas.2414176121.